SCHEMBL4126722

SCHEMBL4126722

Cc1ccc2c3c([nH]c2c1)CCNC3

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.60
TAAR1 Q96RJ0 2/20 0.59
NISCH Q9Y2I1 2/20 0.51
ADRA2A P08913 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA2C P18825 1/20 0.51
HTR7 P34969 1/20 0.51
RAD52 P43351 1/20 0.51
KMT2A Q03164 1/20 0.51
PARP1 P09874 2/20 0.48
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
KDM4E B2RXH2 1/20 0.45
HTR5A P47898 1/20 0.45
NR2E1 Q9Y466 1/20 0.45
CYP3A4 P08684 1/20 0.42
MCHR1 Q99705 1/20 0.42
KIF11 P52732 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31020972 1.00 SIRT2 (0.60) SIRT2TAAR1NISCHADRA2AADRA2B
Hydrochloric Acid SCHEMBL31020957 0.98 TAAR1 (0.62) SIRT2TAAR1NISCHADRA2AADRA2B
Hydrochloric Acid SCHEMBL23828316 0.98 TAAR1 (0.62) SIRT2TAAR1NISCHADRA2AADRA2B
SCHEMBL25512897 0.89 HTR2A (0.60) SIRT2TAAR1NISCHADRA2AADRA2B
SCHEMBL2980946 0.87 NISCH (0.67) SIRT2TAAR1NISCHADRA2AADRA2B
SCHEMBL2980510 0.87 SIRT2 (0.72) SIRT2TAAR1RAD52KMT2AKDM4E
Hydrochloric Acid SCHEMBL11840237 0.86 SIRT2 (0.71) SIRT2TAAR1RAD52KMT2AKDM4E
SCHEMBL20883910 0.81 TAAR1 (0.56) SIRT2TAAR1NISCHADRA2AADRA2B
SCHEMBL21676105 0.81 TAAR1 (0.56) SIRT2TAAR1NISCHADRA2AADRA2B
SCHEMBL18345852 0.81 TAAR1 (0.59) SIRT2TAAR1NISCHADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820867-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2023-09-13 EP disclosed
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2021-09-23 US disclosed
WO-2020012427-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2020-01-16 WO disclosed
WO-2019074979-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF GIRAFPHARMA, LLC (US) 2019-04-18 WO disclosed
WO-2014155300-A2 SUBSTITUED PYRIMIDINE AMINE DERIVATIVES AS TAK-1 INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-10-02 WO disclosed
US-20090023756-A1 SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS PFIZER INC 2009-01-22 US disclosed
US-20090023756-A1 SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS PFIZER INC 2009-01-22 US disclosed
US-20090023756-A1 SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS PFIZER INC 2009-01-22 US disclosed
WO-2007096743-A1 SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS PFIZER PRODUCTS INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023756-A1 SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS PDE12, PDE5A, PDE10A SIRT2 1258/4885TAAR1 1031/4885NISCH 1594/4885
US-20210292324-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCB11, ABCC5 SIRT2 3850/4885TAAR1 3882/4885NISCH 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.